Sugi Predict

Sugi Predict / Compounds / SCHEMBL30608570

SCHEMBL30608570

SCHEMBL30608570

CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GRPR P30550 12/20 0.56
▸ CAPN1 P07384 2/20 0.54
▸ CTSB P07858 2/20 0.54
▸ CXCL8 P10145 5/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30608614 1.00 GRPR (0.56) GRPRCAPN1CTSBCXCL8
SCHEMBL30608605 1.00 GRPR (0.56) GRPRCAPN1CTSBCXCL8
SCHEMBL30608625 0.98 CAPN1 (0.56) GRPRCAPN1CTSBCXCL8
SCHEMBL30608568 0.98 GRPR (0.56) GRPRCAPN1CTSB
SCHEMBL30608559 0.97 CAPN1 (0.56) GRPRCAPN1CTSBCXCL8
SCHEMBL30608615 0.96 CAPN1 (0.57) GRPRCAPN1CTSBCXCL8
SCHEMBL30608622 0.95 GRPR (0.54) GRPRCAPN1CTSBCXCL8
SCHEMBL30608581 0.94 CAPN1 (0.55) CAPN1CTSBCXCL8
SCHEMBL30608567 0.94 CAPN1 (0.60) GRPRCAPN1CTSBCXCL8
SCHEMBL30608592 0.94 CAPN1 (0.60) GRPRCAPN1CTSBCXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646232-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY Université de Genève (CH) 2025-11-12 — — EP claimed
US-20250090637-A1 METHODS OF INHIBITING CEREBRAL INFLAMMATION UNIVERSITÉ DE GENÈVE (CH) 2025-03-20 — — US claimed
WO-2024146707-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY UNIVERSITÉ DE GENÈVE (CH) 2024-07-11 — — WO claimed
EP-3813870-B1 CCR5 INHIBITOR FOR USE IN TREATING CANCER ORION Biotechnology Switzerland Sarl (CH) 2023-11-15 — — EP claimed
EP-3813869-B1 CCR5 INHIBITOR FOR USE IN TREATING A NEUROINFLAMMATORY DISORDER THAT INVOLVES CEREBRAL INFLAMMATION UNIV GENEVE (CH) 2023-10-18 — — EP claimed
EP-4646232-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY Université de Genève (CH) 2025-11-12 — — EP disclosed
US-20250090637-A1 METHODS OF INHIBITING CEREBRAL INFLAMMATION UNIVERSITÉ DE GENÈVE (CH) 2025-03-20 — — US disclosed
CN-112469429-B Use of CCR5 inhibitors in cancer treatment 奥立安生物技术瑞士有限责任公司 2025-02-14 — — CN disclosed
CN-112469430-B Method for inhibiting cerebral inflammation 日内瓦大学 2024-12-24 — — CN disclosed
WO-2024146707-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY UNIVERSITÉ DE GENÈVE (CH) 2024-07-11 — — WO disclosed
EP-3813870-B1 CCR5 INHIBITOR FOR USE IN TREATING CANCER ORION Biotechnology Switzerland Sarl (CH) 2023-11-15 — — EP disclosed
EP-3813869-B1 CCR5 INHIBITOR FOR USE IN TREATING A NEUROINFLAMMATORY DISORDER THAT INVOLVES CEREBRAL INFLAMMATION UNIV GENEVE (CH) 2023-10-18 — — EP disclosed
Send feedback